We have studied the effect of combining inhaled nitric oxide (NO) with an i.v. vasodilator agent, nitroglycerin, or ciloprost, a prostacyclin analogue, during acute pulmonary hypertension in pigs, induced by continuous infusion of a thromboxane analogue (U46619), adjusted to maintain mean pulmonary artery pressure (MPAP) at 40 mm Hg The effects of the different treatments on MPAP and pulmonary resistances were determined. In the first part of the study, we determined the dose-response to increased NO concentrations from 5 to 40 ppm. This showed a maximum pulmonary effect with NO 5 ppm, but with no systemic effects. The effect of NO 10 ppm was then compared with two i.v. drugs. Nitroglycerin was less effective than NO on pulmonary vessels but induced significant arterial hypotension. Pulmonary vasodilatation induced by ciloprost was greater than that by NO but with the same side effects as nitroglycerin on systemic variables. We also found that the combination of NO and nitroglycerin had the same pulmonary effects as NO 10 ppm but that adding ciloprost to NO decreased pulmonary pressures significantly more than either drug used alone. We conclude that inhaled NO may be usefully combined with i.v. ciloprost but not with i.v. nitroglycerin. (Br.
Pulmonary vasoconstriction after cardiopulmonary bypass should be treated rapidly as it causes right ventricular failure [1] . Under normal physiological conditions, the endothelium maintains low pulmonary vascular resistances by producing two potent vasodilators, endothelium-derived relaxing factor (EDRF) and prostacyclin [2] . The effect of these two substances is similar: they relax vascular smooth muscle, although via different pathways. Prostacyclin stimulates adenylate cyclase thus increasing cAMP concentrations [3] . This second messenger activates cAMP-dependent protein kinase to modify phosphorylation of myosin and relax smooth muscle. In contrast, EDRF (which is nitric oxide) stimulates cytoplasmic guanylate cyclase increasing cyclic guanosine monophosphate (cGMP) concentration, which is another second messenger that relaxes vascular smooth muscle, after activation of cGMPdependent protein kinase. The endothelial cell, therefore, plays a crucial role in the control of pulmonary vascular tone, as reviewed recently by Loscalzo [4] .
The inflammatory response initiated by cardiopulmonary bypass activates the granulocytes and their secretion of oxygen radicals damages the endothelial cell, thus contributing to the development of pulmonary hypertension [5] . The release of thromboxane A 2 by platelets and the heparinprotamine reaction further complicate this situation [6] . It has also been shown that the response to a thromboxane analogue (U46619) is increased for 2 days after experimental cardiopulmonary bypass in dogs [7] . Nitrates, prostacyclin or, more recently, inhaled nitric oxide (NO) [8] have been used successfully to treat this acute complication. Recently, it has been reported that inhaled NO associated with prostacyclin could have a synergistic effect in the treatment of pulmonary hypertension associated with correction of a congenital aortic stenosis [9] . Therefore, in this study, we determined if combining inhaled NO with either i.v. nitroglycerin or i.v. ciloprost, a synthetic analogue of prostacyclin (PGI 2 ), would enhance the pulmonary vasodilator effect.
Tidal volume was set at 15 To determine the optimum inhaled NO concentration to be used during comparisons with the i.v. drugs, we established a dose-response curve for NO in our model by increasing the NO concentration from 5 to 40 ppm. Each experiment was therefore separated into seven periods of 20 min starting when a stable condition was observed for at least 10 min after any therapeutic modification: (1) basal status; (2) pulmonary hypertension as described above; (3) inhaled NO concentration set at 5 ppm; (4) at 10 ppm; (5) at 20 ppm; (6) at 40 ppm; and (7) return to the second stage discontinuing NO.
The inhaled NO concentration was increased cumulatively. Haemodynamic variables (MAP, MPAP, LAP, CO) were recorded every 5 min during each period. Seven pigs were included in this preliminary study.
COMPARISON BETWEEN THE EFFECT OF NO 10 PPM AND THE MAXIMUM EFFECT OF EITHER NITROGLYCERIN OR PROSTACYCLIN INFUSION
Pulmonary hypertension was initiated in 14 pigs as described previously and treated for 20 min with 10 ppm of inhaled NO, which was then stopped to allow recovery of pulmonary hypertension. The animal was then allocated randomly to receive either an infusion of nitroglycerin 400 g ml 91 diluted in 5 % glucose (n : 7) or an infusion of ciloprost (Iloprost, Berlex, St Laurent, PQ, Canada) 10 g ml 91 diluted in 0.9 % saline (n : 7 and increased progressively until we observed either a return of MPAP to basal values or a 20 % reduction in basal MAP. When this occurred, the infusion was kept constant for 20 min to record haemodynamic variables and arterial blood-gas tensions. After this period, NO 10 ppm was reintroduced for 20 min to assess any beneficial effect of the combination of the two drugs. All treatments were then discontinued to restore pulmonary hypertension.
Pulmonary (PVR) and systemic (SVR) vascular resistances were calculated, respectively, according to the formulae: 
Results
Data recorded during determination of the doseresponse to inhaled NO are summarized in table 1. MPAP and PVR were increased significantly by U46619 compared with baseline values. However, there were no changes in MAP and SVR after infusion of the thromboxane analogue.
The dose-response curve to inhaled NO 5-40 ppm showed a maximum effect on pulmonary artery pressure at the 5 ppm concentration; increasing NO concentration did not alter significantly either MPAP or PVR compared with the initial concentration. From this dose-response curve and as the effect of inhaled NO reached a plateau starting at 5 ppm, a concentration of 10 ppm of inhaled NO was chosen as supramaximal stimulation to evaluate its effect when combined with the i.v. drugs.
In the second part of the study, when a constant dose of NO 10 ppm was inhaled, pulmonary artery pressure decreased by 29 (2) % in the group receiving nitroglycerin and by 27 (3) % in the group receiving ciloprost, while PVR decreased by 44 (4) % in the nitroglycerin group and by 49 (5) % in the ciloprost group.
Data recorded in the nitroglycerin group are summarized in table 2 and those in the ciloprost  group in table 3, while table 4 Comparing the variations induced by inhaled NO alone with those induced by the combination of inhaled NO and nitroglycerin, there were no significant differences for either MPAP or PVR. The effects observed with the combination of inhaled NO and ciloprost were, however, significantly greater for MPAP and PVR than those recorded when only inhaled NO was provided. This combination was also significantly more effective on these variables than when ciloprost alone was infused. We found that MAP and SVR were not altered significantly by inhaled NO. Infusion of nitroglycerin, however, decreased MAP by 25 (4) % and SVR by 22 (4) % while they decreased by 10 (4) % and 30 (7) %, respectively, with infusion of ciloprost. The combination of inhaled NO with either of the two i.v. agents did not alter significantly MAP or SVR.
Return to baseline MPAP was seen in one of seven pigs treated with nitroglycerin and in five of seven pigs when ciloprost was infused. This suggests that the decrease in SAP was the limiting factor for the increase in infusion in six pigs in the nitroglycerin group and in two pigs in the ciloprost group, these values being significantly different (Fisher's exact test: P : 0.029).
In both groups only inhaled NO improved 
Discussion
In the first part of this study, we confirmed the effectiveness and selectivity of inhaled NO as a pulmonary vasodilator. A concentration of 5 ppm significantly decreased pulmonary pressure with no effect on systemic variables, as described previously by Frostell and colleagues [10] . We also observed that in our model of pulmonary hypertension induced by a thromboxane analogue, increasing the inhaled NO concentration from 5 to 40 ppm did not significantly increase pulmonary vasodilatation.
Our second set of experiments showed that ciloprost appeared to be more effective than inhaled NO or nitroglycerin in reducing pulmonary hypertension while inhaled NO in combination with i.v. nitroglycerin did not enhance its efficacy. In contrast, the combination of inhaled NO and i.v. ciloprost revealed some additive effect of these two drugs.
Nitroglycerin is an i.v. drug used commonly to treat pulmonary hypertension. The use of i.v. nitrovasodilatators is, however, often limited by systemic effects. Inhaled NO has the unique advantage of pulmonary selectivity as it is rapidly inactivated because it is bound tightly to haemoglobin [11] . Moreover, being distributed only to the ventilated regions of the lung, inhaled NO reduces intrapulmonary shunting, as shown by the increase in [12] , but our study did not show this side effect, probably because most of our pigs were free from chest disease and intrapulmonary shunt was minimal [13] .
Nitroglycerin acts only after intracellular release of NO [14] , which implies that these two drugs share the same mechanism of action via activation of the cGMP pathway. Our study suggests that relaxation of the vascular smooth muscle cell by cGMP reaches a plateau, which was achieved in our model with 5 ppm of inhaled NO. This was confirmed further by the fact that adding another i.v. drug which acts via the same pathway did not increase pulmonary vascular dilatation.
Prostacyclin is the other i.v. drug used widely to treat primary or secondary pulmonary hypertension in adults and children [15] . Recently, its aerosolized form has been administered successfully for the treatment of pulmonary hypertension in an animal model [16] and in children suffering from acute respiratory syndrome [17] . Two synthetic analogues with short half-lives have been developed: epoprosterenol and ciloprost. They produce the same pharmacological activities of natural prostacyclin, including peripheral vasodilatation, inhibition of platelet aggregation and some cytoprotection. These compounds bind to membrane prostacyclin receptors and stimulate adenylate cyclase. The subsequent increase in cAMP concentration relaxes smooth muscle. It has also been suggested that prostacyclin hyperpolarizes the membrane of the smooth muscle cell to produce relaxation.
In our study, we observed that ciloprost reversed induced pulmonary hypertension more frequently than nitroglycerin. This does not imply that ciloprost is more powerful than nitroglycerin but that ciloprost has greater pulmonary selectivity, which was confirmed by the fact that the progressive increase in the i.v. infusion was not limited as frequently by systemic hypotension in the ciloprost group compared with the nitroglycerin group; another explanation may be improved cardiac contractility secondary to the increase in the intracellular cAMP concentration, while NO and cGMP have negative inotropic actions [18] .
We found a cumulative effect of ciloprost and inhaled NO on the decrease in MPAP and PVR. The synergistic action between NO and ciloprost has been demonstrated previously on isolated coronary arteries, in which PGI2 relaxation was potentiated by the presence of the vascular endothelium [19] . This effect has also been shown in the hamster microcirculation where the combination of drugs increasing cAMP and drugs increasing cGMP were more effective than either drug alone [20] . This may be explained by the fact that NO activates the GMP pathway whereas ciloprost stimulates adenylate cyclase and the AMP pathway. The combination of NO and ciloprost has been reported to be useful in some case reports [9] but a careful assessment of the benefit of this association has not yet been reported.
